Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
Nina Shah, Li Li, Jessica M McCarty, et al.
British Journal of Haematology (2017) Vol. 177, Iss. 3, pp. 457-466
Open Access | Times Cited: 182

Showing 1-25 of 182 citing articles:

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu, David Marín, Pinaki P. Banerjee, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 6, pp. 545-553
Open Access | Times Cited: 1632
NK cell-based cancer immunotherapy: from basic biology to clinical development
Sizhe Liu, Vasiliy Galat, Yekaterina Galat, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 491
Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Zhu Huang, Robert Blum, Ryan Bjordahl, et al.
Blood (2019) Vol. 135, Iss. 6, pp. 399-410
Open Access | Times Cited: 212
Killers 2.0: NK cell therapies at the forefront of cancer control
Jonathan J. Hodgins, S. Khan, Maria M. Park, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 9, pp. 3499-3510
Open Access | Times Cited: 183
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
John P. Veluchamy, Nina Kok, Hans van Vliet, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 178
Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
Kyle B. Lupo, Sandro Matosevic
Cancers (2019) Vol. 11, Iss. 6, pp. 769-769
Open Access | Times Cited: 167
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy
Emily J. Pomeroy, John Hunzeker, Mitchell G. Kluesner, et al.
Molecular Therapy (2019) Vol. 28, Iss. 1, pp. 52-63
Open Access | Times Cited: 150
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
Erica L. Heipertz, Evan R. Zynda, Tor Espen Stav-Noraas, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 125
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Lucila Nassif Kerbauy, Nancy D. Marín, Mecit Kaplan, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 13, pp. 3744-3756
Open Access | Times Cited: 109
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
Nina Lamers-Kok, Denise Panella, Anna‐Maria Georgoudaki, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 95
Advancing cell-based cancer immunotherapy through stem cell engineering
Yan-Ruide Li, Zachary Spencer Dunn, Yanqi Yu, et al.
Cell stem cell (2023) Vol. 30, Iss. 5, pp. 592-610
Open Access | Times Cited: 41
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Andreas T. Björklund, Mattias Carlsten, Ebba Sohlberg, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 8, pp. 1834-1844
Open Access | Times Cited: 156
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 120
Cellular therapy: Adoptive immunotherapy with expanded natural killer cells
Dean A. Lee
Immunological Reviews (2019) Vol. 290, Iss. 1, pp. 85-99
Closed Access | Times Cited: 111
Adult Stem Cells for Regenerative Therapy
Narasimman Gurusamy, Abdulrhman Alsayari, Sheeja Rajasingh, et al.
Progress in molecular biology and translational science (2018), pp. 1-22
Closed Access | Times Cited: 110
Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells
Lara Herrera, Silvia Santos, Miguel Ángel Vesga, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 96
Adoptive cell therapy using engineered natural killer cells
Katayoun Rezvani
Bone Marrow Transplantation (2019) Vol. 54, Iss. S2, pp. 785-788
Open Access | Times Cited: 92
CAR‐NK cells: the next wave of cellular therapy for cancer
May Daher, Luciana Melo Garcia, Ye Li, et al.
Clinical & Translational Immunology (2021) Vol. 10, Iss. 4
Open Access | Times Cited: 92
Tissue-Resident NK Cells: Development, Maturation, and Clinical Relevance
Elaheh Hashemi, Subramaniam Malarkannan
Cancers (2020) Vol. 12, Iss. 6, pp. 1553-1553
Open Access | Times Cited: 87
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity
Hind Rafei, May Daher, Katayoun Rezvani
British Journal of Haematology (2020) Vol. 193, Iss. 2, pp. 216-230
Open Access | Times Cited: 85
NK cells to cure cancer
Clara Di Vito, Joanna Mikulak, Elisa Zaghi, et al.
Seminars in Immunology (2019) Vol. 41, pp. 101272-101272
Closed Access | Times Cited: 81
HLA-DR-expressing NK cells: Effective killers suspected for antigen presentation
Sofya A. Erokhina, Maria A. Streltsova, Leonid M. Kanevskiy, et al.
Journal of Leukocyte Biology (2020) Vol. 109, Iss. 2, pp. 327-337
Closed Access | Times Cited: 70
Generating natural killer cells for adoptive transfer: expanding horizons
Soumyadipta Kundu, Mark E. Gurney, Michael O’Dwyer
Cytotherapy (2021) Vol. 23, Iss. 7, pp. 559-566
Open Access | Times Cited: 61
Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
Margaret Lamb, Hemalatha G. Rangarajan, Brian P. Tullius, et al.
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 59
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Antonio Valeri, Almudena García-Ortiz, Eva Castellano, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 56
Page 1 - Next Page

Scroll to top